Literature DB >> 25022814

The management of patients with polycystic ovary syndrome.

Channa N Jayasena1, Stephen Franks2.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. The syndrome is typified by its heterogeneous presentation, which includes hirsutism (a function of hypersecretion of ovarian androgens), menstrual irregularity and infertility (that is due to infrequent or absent ovulation). Furthermore, PCOS predisposes patients to metabolic dysfunction and an increased risk of type 2 diabetes mellitus (T2DM). The aetiology of the syndrome has a major genetic component. Obesity exacerbates the insulin resistance that is a feature of PCOS in many women and amplifies the clinical and biochemical abnormalities. In clinical practice, the choice of investigations to be done depends mainly on the presenting symptoms. The approach to management is likewise dependent on the presenting complaint. Symptoms of androgen excess (hirsutism, acne and alopecia) require cosmetic measures, suppression of ovarian androgen function and anti-androgen therapy, alone or in combination. Ovulation rate is improved by diet and lifestyle intervention in overweight individuals but induction of ovulation by, in the first instance, anti-estrogens is usually required. Monitoring of glucose is important in overweight women and/or those with a family history of T2DM. Metformin is indicated for women with impaired glucose tolerance but whether this drug is otherwise useful in women with PCOS remains debatable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25022814     DOI: 10.1038/nrendo.2014.102

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  168 in total

1.  Antiandrogenic effect of spirolactones: mechanism of action.

Authors:  P Corvol; A Michaud; J Menard; M Freifeld; J Mahoudeau
Journal:  Endocrinology       Date:  1975-07       Impact factor: 4.736

Review 2.  Anti-Müllerian hormone and ovarian dysfunction.

Authors:  Frank J Broekmans; Jenny A Visser; Joop S E Laven; Simone L Broer; Axel P N Themmen; Bart C Fauser
Journal:  Trends Endocrinol Metab       Date:  2008-09-18       Impact factor: 12.015

3.  Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.

Authors:  C G Solomon; F B Hu; A Dunaif; J Rich-Edwards; W C Willett; D J Hunter; G A Colditz; F E Speizer; J E Manson
Journal:  JAMA       Date:  2001-11-21       Impact factor: 56.272

Review 4.  Thiazolidinediones in the treatment of insulin resistance and type II diabetes.

Authors:  A R Saltiel; J M Olefsky
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

5.  Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes.

Authors:  S Goya Wannamethee; A Gerald Shaper; Mary Walker
Journal:  J Epidemiol Community Health       Date:  2005-02       Impact factor: 3.710

6.  Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells.

Authors:  Israel Ortega; Amanda B Cress; Donna H Wong; Jesus A Villanueva; Anna Sokalska; Ben C Moeller; Scott D Stanley; Antoni J Duleba
Journal:  Biol Reprod       Date:  2012-01-30       Impact factor: 4.285

7.  Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3.

Authors:  Zi-Jiang Chen; Han Zhao; Lin He; Yuhua Shi; Yingying Qin; Yongyong Shi; Zhiqiang Li; Li You; Junli Zhao; Jiayin Liu; Xiaoyan Liang; Xiaoming Zhao; Junzhao Zhao; Yingpu Sun; Bo Zhang; Hong Jiang; Dongni Zhao; Yuehong Bian; Xuan Gao; Ling Geng; Yiran Li; Dongyi Zhu; Xiuqin Sun; Jin-E Xu; Cuifang Hao; Chun-E Ren; Yajie Zhang; Shiling Chen; Wei Zhang; Aijun Yang; Junhao Yan; Yuan Li; Jinlong Ma; Yueran Zhao
Journal:  Nat Genet       Date:  2010-12-12       Impact factor: 38.330

8.  Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.

Authors:  E O Talbott; J V Zborowski; J R Rager; M Y Boudreaux; D A Edmundowicz; D S Guzick
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

9.  Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects.

Authors:  Y Arad; L A Spadaro; K Goodman; A Lledo-Perez; S Sherman; G Lerner; A D Guerci
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

10.  Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis.

Authors:  Daniel Izquierdo; Nastaran Foyouzi; Jakub Kwintkiewicz; Antoni J Duleba
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

View more
  49 in total

Review 1.  The developmental origins of the mammalian ovarian reserve.

Authors:  Kathryn J Grive; Richard N Freiman
Journal:  Development       Date:  2015-08-01       Impact factor: 6.868

2.  Obesity Education Strategies for Cancer Prevention in Women's Health.

Authors:  Lucy Liu; Abraham Segura; Andrea R Hagemann
Journal:  Curr Obstet Gynecol Rep       Date:  2015-10-13

Review 3.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

4.  Association of single nucleotide polymorphisms in the RAB5B gene 3'UTR region with polycystic ovary syndrome in Chinese Han women.

Authors:  Jia Yu; Caifei Ding; Siqi Guan; Chenye Wang
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

5.  Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements.

Authors:  Yabo Yang; Miao Ding; Na Di; Ricardo Azziz; Dongzi Yang; Xiaomiao Zhao
Journal:  J Clin Lab Anal       Date:  2018-10-23       Impact factor: 2.352

6.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

7.  Anti-Müllerian hormone gene polymorphism is associated with androgen levels in Chinese polycystic ovary syndrome patients with insulin resistance.

Authors:  Meng-Xue Zheng; Yan Li; Rong Hu; Fei-Miao Wang; Xiao-Mei Zhang; Bing Guan
Journal:  J Assist Reprod Genet       Date:  2016-01-06       Impact factor: 3.412

8.  Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome.

Authors:  Mehmet Calan; Ozgur Yilmaz; Tuncay Kume; Gokcen Unal Kocabas; Pinar Yesil Senses; Yasar Mehmet Senses; Muzaffer Temur; Ozlem Gursoy Calan
Journal:  Endocrine       Date:  2016-02-01       Impact factor: 3.633

9.  Genome-wide methylation profiling in granulosa lutein cells of women with polycystic ovary syndrome (PCOS).

Authors:  E Makrinou; A W Drong; G Christopoulos; A Lerner; I Chapa-Chorda; T Karaderi; S Lavery; K Hardy; C M Lindgren; S Franks
Journal:  Mol Cell Endocrinol       Date:  2019-10-07       Impact factor: 4.102

10.  Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.

Authors:  Hsuan Yen; Yu-Tung Chang; Fui-Jun Yee; Yu-Chen Huang
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.